Arbutus Biopharma Corporation
ABUS
$2.75
$0.0351.29%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -53.51% | -38.19% | -29.47% | 54.39% | 255.11% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -53.51% | -38.19% | -29.47% | 54.39% | 255.11% |
| Cost of Revenue | -12.69% | -1.97% | 2.13% | 20.00% | 28.86% |
| Gross Profit | -22.41% | -27.19% | -26.11% | -4.86% | 16.74% |
| SG&A Expenses | 26.02% | 18.93% | 2.13% | 1.90% | 4.07% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -5.93% | 1.88% | 2.13% | 16.28% | 23.72% |
| Operating Income | -23.43% | -24.80% | -18.91% | -4.06% | 11.76% |
| Income Before Tax | -12.05% | -17.19% | -10.52% | 1.63% | 14.74% |
| Income Tax Expenses | -- | -100.00% | -100.00% | -100.00% | -- |
| Earnings from Continuing Operations | -4.89% | -9.62% | -3.54% | 7.41% | 8.91% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.89% | -9.62% | -3.54% | 7.41% | 8.91% |
| EBIT | -23.43% | -24.80% | -18.91% | -4.06% | 11.76% |
| EBITDA | -24.00% | -25.75% | -19.95% | -4.68% | 11.59% |
| EPS Basic | 4.42% | 3.53% | 23.76% | 38.96% | 45.82% |
| Normalized Basic EPS | -5.71% | -2.97% | 11.12% | 27.68% | 41.30% |
| EPS Diluted | 4.99% | 4.89% | 24.70% | 39.57% | 45.61% |
| Normalized Diluted EPS | -5.71% | -2.97% | 11.12% | 27.68% | 41.30% |
| Average Basic Shares Outstanding | 9.94% | 11.90% | 19.25% | 28.53% | 42.05% |
| Average Diluted Shares Outstanding | 9.94% | 11.90% | 19.25% | 28.53% | 42.05% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
